AbbVie has announced the completion of the acquisition of Celsius Therapeutics. As per the agreement, AbbVie has acquired all outstanding shares of Celsius for USD 250 million, subject to certain customary adjustments.
Post acquisition, AbbVie plans to further advance the development of Celsius’ CEL383, , a potential first-in-class anti-TREM1 antibody that has completed a Phase I clinical trial for inflammatory bowel disease (IBD). The company states that the acquisition of Celsius and its potential drug, CEL383, is a promising step toward a new approach in IBD treatment.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.